<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37463787</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2059-7908</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>BMJ global health</Title><ISOAbbreviation>BMJ Glob Health</ISOAbbreviation></Journal><ArticleTitle>Estimating the economic burden of long-Covid: the additive cost of healthcare utilisation among COVID-19 recoverees in Israel.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e012588</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjgh-2023-012588</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Postacute sequelae resulting from SARS-CoV-2 infections (LONG-COVID) have been reported. The resulting added economic burden from the perspective of healthcare organisations is not clear. Therefore, this study aims to evaluate the additive healthcare costs among COVID-19 recoverees, in a large community-dwelling general population, as incurred by an insurer-provider organisation over time.</AbstractText><AbstractText Label="METHODS">In this historical cohort study, cost data from Clalit Health Services (CHS) were analysed. The primary endpoint was the direct cost incurred by CHS per month per person. Costs were measured for COVID-19 recoverees and matched controls, from January 2019 to January 2022. Difference in differences (DiDs) were calculated as the difference in mean monthly costs in cases and controls in the post-COVID-19 individual period, deducing their cost difference in a prepandemic 12 months baseline period.</AbstractText><AbstractText Label="RESULTS">Among N=642 868 community-dwelling COVID-19 recoverees, 268 948 (40.8%) were 0-19 years old and 63 051 (9.6%) were 60 years or older. A total of 16 017 (2.5%) of recoverees had been hospitalised during the acute phase of the COVID-19 disease. Costs in cases and controls converged after 16 months from recovery. The mean monthly cost incurred by CHS per COVID-19 recoverees over up to 15 months (mean: 8.25) of post-COVID-19 follow-up was higher by 8.2% (US$8.2) compared with matched controls. The excess cost attributable to post-COVID-19 effects (DID) was 7.6% of the cost in controls (US$7.7 per patient per month). Both net and relative DIDs were substantially higher in patients who required hospitalisation during the acute phase of COVID-19 and in older adults. Excess in hospitalisations, primary care physicians and medical specialists' visits-related costs were observed.</AbstractText><AbstractText Label="CONCLUSIONS">Long-term effects of SARS-CoV-2 infections translate into excess healthcare costs, months after recovery, hence requiring adjustments of funds allocation. These excess costs gradually diminish after recoveree, returning to baseline differences 16 months after recoveree.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolff Sagy</LastName><ForeName>Yael</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-2007-343X</Identifier><AffiliationInfo><Affiliation>Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel yael.wo@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feldhamer</LastName><ForeName>Ilan</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brammli-Greenberg</LastName><ForeName>Shuli</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Braun School of Public Health and Community Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lavie</LastName><ForeName>Gil</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Branch of Planning and Strategy, Clalit Health Services, Tel Aviv, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Glob Health</MedlineTA><NlmUniqueID>101685275</NlmUniqueID><ISSNLinking>2059-7908</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007557" MajorTopicYN="N" Type="Geographic">Israel</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086522" MajorTopicYN="N">Financial Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003695" MajorTopicYN="N">Delivery of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">health economics</Keyword><Keyword MajorTopicYN="N">health services research</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>21</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>19</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>18</Day><Hour>21</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37463787</ArticleId><ArticleId IdType="pmc">PMC10357303</ArticleId><ArticleId IdType="doi">10.1136/bmjgh-2023-012588</ArticleId><ArticleId IdType="pii">bmjgh-2023-012588</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen S, Prettner K, Kuhn M, et al. . The economic burden of COVID-19 in the United States: estimates and projections under an infection-based herd immunity approach. J Econ Ageing 2021;20:100328. 10.1016/j.jeoa.2021.100328</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jeoa.2021.100328</ArticleId><ArticleId IdType="pmc">PMC8186726</ArticleId><ArticleId IdType="pubmed">34123719</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler DM, Summers LH. The COVID-19 pandemic and the $16 trillion virus. JAMA 2020;324:1495&#x2013;6. 10.1001/jama.2020.19759</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.19759</ArticleId><ArticleId IdType="pmc">PMC7604733</ArticleId><ArticleId IdType="pubmed">33044484</ArticleId></ArticleIdList></Reference><Reference><Citation>Briggs A, Vassall A. Count the cost of disability caused by COVID-19. Nature 2021;593:502&#x2013;5. 10.1038/d41586-021-01392-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01392-2</ArticleId><ArticleId IdType="pubmed">34040204</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikkelsen ME, Abramoff B. COVID-19: evaluation and management of adults with persistent symptoms following acute illness (long COVID). UpToDate
2022. Available: https://www.uptodate.com/contents/covid-19-evaluation-and-management-of-adults-with-persistent-symptoms-following-acute-illness-long-covid</Citation></Reference><Reference><Citation>Ayoubkhani D, Munro M. n.d.
Prevalence of ongoing symptoms following Coronavirus (COVID-19) infection in the UK. data and analyses from census 2021: 3 March 2022. office of national statistics, UK. Available: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronavirusCovid19infectionintheuk/3march2022</Citation></Reference><Reference><Citation>Morin L, Savale L, Pham T, et al. . Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021;325:1525&#x2013;34. 10.1001/jama.2021.3331</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3331</ArticleId><ArticleId IdType="pmc">PMC7970386</ArticleId><ArticleId IdType="pubmed">33729425</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T, Hittle M, Goodman SN. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: A systematic review. JAMA Netw Open 2021;4:e2111417. 10.1001/jamanetworkopen.2021.11417</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11417</ArticleId><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M, Manoharan L, Elkheir N, et al. . Characterizing long COVID: a living systematic review. BMJ Glob Health 2021;6:e005427. 10.1136/bmjgh-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans RA, McAuley H, Harrison EM, et al. . Physical, cognitive, and mental health impacts of COVID-19 after Hospitalisation (PHOSP-COVID): a UK Multicentre, prospective cohort study. Lancet Respir Med 2021;9:1275&#x2013;87. 10.1016/S2213-2600(21)00383-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00383-0</ArticleId><ArticleId IdType="pmc">PMC8497028</ArticleId><ArticleId IdType="pubmed">34627560</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. . 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet 2021;398:747&#x2013;58. 10.1016/S0140-6736(21)01755-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)01755-4</ArticleId><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, et al. . 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related Hospitalisation: a prospective study. Lancet Respir Med 2021;9:747&#x2013;54. 10.1016/S2213-2600(21)00174-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00174-0</ArticleId><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021;594:259&#x2013;64. 10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K, Ren S, Heath K, et al. . Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-Cov-2 infection: retrospective cohort study BMJ. BMJ 2022:e068414. 10.1136/bmj-2021-068414</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068414</ArticleId><ArticleId IdType="pmc">PMC8828141</ArticleId><ArticleId IdType="pubmed">35140117</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen B, Waitzberg R, Merkur S. Israel &#x2013; health system review. Health Syst Transit 2015;17:1&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">27050102</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof SY, Malden DE, Liu I-LA, et al. . Health care utilization in the 6 months following SARS-Cov-2 infection. JAMA Netw Open 2022;5:e2225657. 10.1001/jamanetworkopen.2022.25657</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.25657</ArticleId><ArticleId IdType="pmc">PMC9375168</ArticleId><ArticleId IdType="pubmed">35960522</ArticleId></ArticleIdList></Reference><Reference><Citation>Abadie A. Semiparametric difference-in-differences Estimators. Rev Econ Stud 2005;72:1&#x2013;19. 10.1111/0034-6527.00321</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/0034-6527.00321</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor CO, Lemke KW, Richards TM, et al. . Comorbidity characterization among eMERGE institutions: A pilot evaluation with the Johns Hopkins adjusted clinical groups&#xae; system. AMIA Jt Summits Transl Sci Proc 2019;2019:145&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6568092</ArticleId><ArticleId IdType="pubmed">31258966</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi B, Sudry T, Flaks-Manov N, et al. . Long Covid outcomes at one year after mild SARS-Cov-2 infection: nationwide cohort study. BMJ 2023;380:e072529. 10.1136/bmj-2022-072529</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-072529</ArticleId><ArticleId IdType="pmc">PMC9832503</ArticleId><ArticleId IdType="pubmed">36631153</ArticleId></ArticleIdList></Reference><Reference><Citation>Moynihan R, Sanders S, Michaleff ZA, et al. . Impact of COVID-19 pandemic on utilisation of Healthcare services: a systematic review. BMJ Open 2021;11:e045343. 10.1136/bmjopen-2020-045343</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-045343</ArticleId><ArticleId IdType="pmc">PMC7969768</ArticleId><ArticleId IdType="pubmed">33727273</ArticleId></ArticleIdList></Reference><Reference><Citation>Howarth A, Munro M, Theodorou A, et al. . Trends in Healthcare utilisation during COVID-19: a longitudinal study from the UK. BMJ Open 2021;11:e048151. 10.1136/bmjopen-2020-048151</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048151</ArticleId><ArticleId IdType="pmc">PMC8327639</ArticleId><ArticleId IdType="pubmed">34330859</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagy YW, Cicurel A, Battat E, et al. . The impact of COVID-19 pandemic on emergency Department visits and associated mortality during 14 months of the pandemic in Israel. Intern Emerg Med 2022;17:1699&#x2013;710. 10.1007/s11739-022-02991-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11739-022-02991-1</ArticleId><ArticleId IdType="pmc">PMC9108137</ArticleId><ArticleId IdType="pubmed">35576046</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L, Baca S, Saydah S, et al. . Post&#x2013;COVID conditions among adult COVID-19 survivors aged 18&#x2013;64 and &#x2265;65 years&#x2014;United States. MMWR Morb Mortal Wkly Rep 2020;71:713&#x2013;7. 10.15585/mmwr.mm7121e1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7121e1</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention . Long COVID: household pulse survey. 2022. Available: https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm</Citation></Reference><Reference><Citation>Tene L, Bergroth T, Eisenberg A, et al. . Risk factors, health outcomes, Healthcare services utilization, and direct medical costs of patients with long COVID. Int J Infect Dis 2023;128:3&#x2013;10. 10.1016/j.ijid.2022.12.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.12.002</ArticleId><ArticleId IdType="pubmed">36529373</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et al. . Risk of long COVID associated with Delta versus Omicron variants of SARS-Cov-2. Lancet 2022;399:2263&#x2013;4. 10.1016/S0140-6736(22)00941-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho S. Long COVID could cost the economy trillions, experts predict. n.d.
Available: https://www.webmd.com/covid/news/20220928/long-covid-could-cost-economy-trillions-experts</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>